Arvinas Share Price Today

Arvinas files for $400 million mixed shelf offering

Arvinas Inc filed a shelf registration for up to $400 million in securities. The mixed shelf includes common stock, preferred stock, and debt instruments. Proceeds are designated for general corporate purposes upon future issuance.

HC Wainwright maintains Buy on Arvinas, cuts price target to $13

HC Wainwright & Co. maintains a Buy rating on Arvinas. Price target lowered from $18 to $13 by analyst Andres Y. Maldonado.

Arvinas Q3FY26 Results: Cash at $558.9M, non-GAAP expenses down 25%

Cash and equivalents stood at $558.9 million as of Q3FY26, providing runway into H2 2028. Non-GAAP expenses declined 25% YoY to $53.5 million, driven by cuts in R&D and G&A. First royalty of $0.5 million booked under license agreement with Rigel. Key clinical data for ARV393, ARV027, and ARV6723 scheduled for 2027 disclosures.

Arvinas shares Phase 1 ARV-102 data showing LRRK2 degradation

Final Phase 1 data for ARV-102 showed dose-dependent improvements in saccadic hypometria in Parkinson's patients. Oral doses of 20 mg to 80 mg degraded LRRK2 in the central nervous system over 28 days. Reductions in CSF LRRK2 levels correlated with improved oculomotor function and synaptic biomarker changes. Data supports continued evaluation of ARV-102 as a potential therapeutic approach for LRRK2-associated diseases.

Arvinas grants 64,766 options and 42,388 RSUs to new hire

Arvinas granted 64,766 stock options and 42,388 RSUs to a single new employee. Option exercise price set at $7.51 per share, equal to the closing price on September 28, 2026. Options vest over four years with a one-year cliff; RSUs vest in four annual installments. Grants issued under Nasdaq Listing Rule 5635(c)(4), outside the standard stock incentive plan.

Arvinas doses first patient in Phase 1/2 trial of immuno-oncology candidate ARV-6723

Arvinas doses first patient in Phase 1/2 trial of ARV-6723. ARV-6723 is an oral PROTAC targeting HPK1 in advanced solid tumors. Trial evaluates monotherapy and combination with pembrolizumab. Preclinical data shows activity in anti-PD-1 resistant models.